# Hematology/Oncology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Irène Joliot-Curie (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-RB003-SYN-TD
- Date: 1955-09-16
- Fictional facility: St. Posthumous Health Center
- Fictional author: Tobias Engquist-Mensah, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Solène Marchand-Ellis, MD

## Reason for consultation

Pancytopenia with 12 percent blasts on the blood smear in a 58-year-old nuclear physicist with about four decades of occupational exposure to ionizing radiation and treated tuberculosis. Please confirm the diagnosis by bone marrow, classify it, assess her fitness, and plan treatment, transfusion and infection prevention. **S**

## History

Mrs. Joliot-Curie, a 58-year-old nuclear physicist, is seen at the request of Dr. Marchand-Ellis two days after pancytopenia with circulating blasts was found. She describes two months of tiredness, then bruising and gum bleeding, and in the last two days breathlessness on one flight of stairs. She has had no fever, bone pain, or weight loss. Her occupational history is long: X-ray work early in her career, decades of laboratory work with polonium and other radioactive sources, and the rupture of a sealed polonium source on her bench about ten years ago, she does not know what dose she received from it; her monitored doses are recorded by her employer. Pulmonary tuberculosis in her forties was treated to completion, and she has been breathless on stairs since. She has never smoked and takes no medicines. Her mother died of aplastic anemia attributed to radiation. She wants the evidence and the numbers, and wants to keep working with her mind for as long as she can. **S**

## Examination

| System | Finding |
|---|---|
| General | Pale and tired but alert; weight 53.8 kg |
| Skin | Bruises on the thighs and shins; petechiae on the lower legs |
| Mouth | Gum petechiae; no gum infiltration |
| Lymph nodes | None enlarged |
| Respiratory | Fine crackles at the right apex |
| Abdomen | No enlarged liver or spleen |

BP 114/68 mmHg; pulse 100 bpm; respirations 18/min; temperature 37.3 °C; oxygen saturation 97% on room air; weight 53.8 kg; BMI 20.2 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Marchand-Ellis's intake note and results. Today: white cells 1.9 with neutrophils 0.5 x10^3/uL, hemoglobin 7.1 g/dL, platelets 22 x10^3/uL, blasts 14 percent on the smear; INR 1.1, fibrinogen 310 mg/dL. Bone marrow aspirate this morning: 34 percent myeloblasts with dysplasia in the red cell and megakaryocyte lines; flow cytometry shows myeloid blasts positive for CD34, CD117, CD13, CD33, HLA-DR and MPO; rapid PML::RARA FISH negative. Cytogenetics and a myeloid next-generation sequencing panel are pending. Chest X-ray this morning: old fibrotic scarring at the right apex, no active disease. White cell count: 1.9 10*3/uL (low); Absolute neutrophil count: 0.5 10*3/uL (low); Hemoglobin: 7.1 g/dL (low); Platelets: 22 10*3/uL (low); Blood blasts (smear): 14% (high); Bone marrow blasts: 34% (high); INR: 1.1; Fibrinogen: 310 mg/dL. All results are synthetic.

## Assessment

1. **Acute myeloid leukemia** (C92.00). Confirmed: 34 percent marrow myeloblasts of myeloid phenotype. Acute promyelocytic leukemia is excluded by the phenotype, the normal coagulation tests and the negative rapid PML::RARA test, so there is no need for emergency all-trans retinoic acid. The multilineage dysplasia and the macrocytosis suggest a leukemia arising from a damaged marrow. Classification and risk await the cytogenetics and molecular panel. After long exposure to ionizing radiation, the most likely findings are a complex karyotype, loss of 5q or 7, and a TP53 mutation, which would mean adverse risk. The WHO and ICC labels for leukemia after cytotoxic therapy (therapy-related) are defined by earlier chemotherapy or radiotherapy given as treatment, so her leukemia should be classified by its genetics and her occupational exposure recorded in the history rather than as a therapy-related label. **S**
2. **Past tuberculosis and fitness** (Z86.11). ECOG 1 today, but her lung reserve may be reduced by old tuberculous scarring; lung function with diffusing capacity, an echocardiogram and an ECG are needed before choosing induction. If her diffusing capacity is 65 percent of predicted or less, or her performance status falls to 2, she would be outside the trial definition of fitness for intensive induction. The chest X-ray shows no active tuberculosis; treated disease needs no preventive therapy, but new respiratory symptoms during neutropenia should be investigated promptly. **S**
3. **Occupational exposure to ionizing radiation** (Z57.1). A recognized risk factor for myeloid leukemia, consistent with her history. Her employer must keep her dose records and give them to her on request. **S**

## Recommendations

1. Cytogenetics, a myeloid sequencing panel (including FLT3, NPM1, IDH1, IDH2, TP53 and CEBPA) and FISH from today's marrow; classify by both WHO 1951 and ICC 1951 and assign ELN 1951 genetic risk when results are back, in about ten days.
2. Echocardiogram, ECG and lung function tests with diffusing capacity on the day of the results review.
3. If the genetics are adverse (for example TP53-mutated or complex karyotype) or she is unfit for intensive induction, azacitidine 75 mg/m2 on days 1 to 7 with venetoclax in 28-day cycles; if she is fit and the genetics are favorable or intermediate, intensive induction would be offered. Either way, discuss clinical trials.
4. With venetoclax, admit for the ramp-up with tumor lysis monitoring, allopurinol and fluids; with posaconazole, give venetoclax 70 mg daily after the ramp-up; marrow on day 21 to 28, holding venetoclax until counts recover if the marrow is clear.
5. Transfusion: irradiated, leukoreduced products; red cells one unit at a time for hemoglobin below 7 to 8 g/dL or symptoms (one unit today); platelets for a count below 10 x10^3/uL or bleeding; no platelet transfusion was needed for today's biopsy.
6. Prophylaxis once treatment starts: posaconazole (mold-active, because neutropenia will be prolonged), acyclovir, and levofloxacin while neutrophils are below 0.5; a written fever plan now.
7. Hepatitis B (surface antigen, core antibody, surface antibody), hepatitis C and HIV tests before therapy, and HLA typing now.
8. She is a potential candidate for a reduced-intensity allogeneic transplant in first remission, especially with adverse genetics: transplant center evaluation and an unrelated donor search at the start of treatment.
9. Specialist palliative care from the start of treatment, alongside it, for symptoms, prognosis and her goals.
10. Document the occupational history in full and request her dosimetry and bioassay records in writing from the employer's radiation safety office.

## Strengths and supports

- Supports: a close family, long-standing colleagues, and work she believes in **S**

## Communication

Discussed with Dr. Marchand-Ellis, who saw her the same day. The diagnosis and what the pending tests will decide were explained to Mrs. Joliot-Curie in plain terms with the numbers she asked for; she took notes and asked for the trial reports. **S**

## Follow-up

Results review in about ten days with Dr. Marchand-Ellis, with the genetics, echocardiogram and lung function tests, to decide induction; the hematology/oncology team will lead treatment and see her through each cycle. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Acute Myeloid Leukemia, Version 5.2026 (2026), National Comprehensive Cancer Network
- Döhner H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022 (PMID 35797463) (2022), European LeukemiaNet (Blood)
- Khoury JD, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022 (PMID 35732831) (2022), World Health Organization (Leukemia)
- Arber DA, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022 (PMID 35767897) (2022), International Consensus Classification (Blood)
- DiNardo CD, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia (VIALE-A). N Engl J Med 2020 (PMID 32786187) (2020), New England Journal of Medicine
- NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections (2026), National Comprehensive Cancer Network
- Sanders JJ, et al. Palliative Care for Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2024 (PMID 38748941) (2024), American Society of Clinical Oncology
- Carson JL, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA 2023 (PMID 37824153) (2023), Association for the Advancement of Blood and Biotherapies (JAMA)
- Kaufman RM, et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015 (PMID 25383671) (2015), AABB (Annals of Internal Medicine)
- Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (PMID 32716741) (2020), American Society of Clinical Oncology
- 10 CFR 19.13, Notifications and reports to individuals (radiation exposure reports on request) (2026), U.S. Nuclear Regulatory Commission (Electronic Code of Federal Regulations)
- 29 CFR 1910.1096, Ionizing radiation (records of exposure and disclosure to employees) (2026), Occupational Safety and Health Administration
